This study aims to elucidate the therapeutic efficacy of electroacupuncture in managing chemotherapy-induced gastrointestinal symptom clusters through clinical research. Building upon this foundation, multi-omics analyses will be conducted to investigate the regulatory effects and underlying mechanisms of electroacupuncture on gastrointestinal symptoms. Ultimately, genomic studies will be performed to further clarify the key targets of electroacupuncture intervention, thereby providing high-level evidence-based medical support and theoretical foundations for optimizing electroacupuncture strategies in addressing chemotherapy-induced gastrointestinal symptoms in patients with cancer.
Pathologically confirmed stage I-III breast cancer;
An Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
Age between 18 and 75 years;
Scheduled to receive highly emetogenic chemotherapy regimens, such as EC (epirubicin + cyclophosphamide) or platinum-based regimens, during the first cycle of neoadjuvant/adjuvant chemotherapy;
Patients with advanced-stage cancer;
Those undergoing concurrent chemoradiotherapy;
Individuals with severe impairment of vital organ function who cannot tolerate standard-dose chemotherapy;
Patients with contraindications to acupuncture, such as active skin infections;
Jiuda Zhao
Lead sponsor
Affiliated Hospital of Qinghai University
Sponsor institution